Health ❯ Nutrition ❯ Weight Loss ❯ Pharmaceuticals

Semaglutide

New Evidence Flags Rapid Weight Regain After Stopping GLP-1 Drugs

The evidence puts long-term adherence at the center of obesity care.

U.S. Obesity Rate Drops to 37% as GLP-1 Use Surges, Gallup Finds

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects